Scrip
Hopes high for Provenge to become first US-approved therapeutic cancer vaccine
01 May 2009
Malini Guha
Please Login to read the full article.
01 May 2009
Malini Guha
Dendreon's closely watched novel cancer therapy Provenge (sipuleucel-T) could become the first targeted therapeutic cancer vaccine to be approved in the US after it improved median overall survival by about four months to almost 26 months in men with advanced, hormone-refractory (androgen-independent)...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Sanofi-Aventis's new chemotherapy drug Jevtana improves survival in advanced prostate cancer
- Avastin fails only Phase III trial in advanced prostate cancer
- Dendreon's Provenge prolongs prostate cancer survival in Phase III
- Dendreon to raise up to $448 million to fund Provenge commercialisation
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
